Rimini Street to Report First Quarter 2024 Financial Results on May 2, 2024
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, products and services, the leading third-party support provider for Oracle and SAP software, and a Salesforce and AWS partner, today announced it will report earnings prior to market open on May 2, 2024. The company will host a conference call and webcast on that date to discuss the first quarter 2024 results and the 2024 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240403799490/en/
(Graphic: Business Wire)
A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184.
A replay of the webcast will be available for one year following the event.
About Rimini Street, Inc.
Rimini Street, Inc. (Nasdaq: RMNI), a Russell 2000® Company, is a global provider of end-to-end enterprise software support, products and services, the leading third-party support provider for Oracle and SAP software and a Salesforce and AWS partner. The Company has operations globally and offers a comprehensive family of unified solutions to run, manage, support, customize, configure, connect, protect, monitor, and optimize enterprise application, database, and technology software, and enables clients to achieve better business outcomes, significantly reduce costs and reallocate resources for innovation. To date, over 5,500 Fortune 500, Fortune Global 100, midmarket, public sector, and other organizations from a broad range of industries have relied on Rimini Street as their trusted enterprise software solutions provider. To learn more, please visit http://www.riministreet.com, and connect with Rimini Street on Twitter, Facebook and LinkedIn.
© 2024 Rimini Street, Inc. All rights reserved. “Rimini Street” is a registered trademark of Rimini Street, Inc. in the United States and other countries, and Rimini Street, the Rimini Street logo, and combinations thereof, and other marks marked by TM are trademarks of Rimini Street, Inc. All other trademarks remain the property of their respective owners, and unless otherwise specified, Rimini Street claims no affiliation, endorsement, or association with any such trademark holder or other companies referenced herein.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240403799490/en/
Contact information
Investor Relations Contact
Dean Pohl
Rimini Street, Inc.
+1 (925) 523-7636
IR@riministreet.com
Media Relations Contact
Janet Ravin
Rimini Street, Inc.
+1 (702) 285-3532
PR@riministreet.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SK Capital Completes Acquisition of LISI Group’s Medical Division and Launches New Platform as Precera Medical3.11.2025 13:30:00 EET | Press release
SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the specialty materials, ingredients, and life sciences sectors, has completed the previously announced acquisition of LISI Group’s (Euronext: FII) Medical division (the “Transaction”). The business has relocated its headquarters to Big Lake, Minnesota and has been renamed Precera Medical (“Precera Medical” or the “Company”), marking its emergence as a leading contract development and manufacturing organization (“CDMO”) partner for blue chip medical device original equipment manufacturers (“OEMs”) and innovators. As part of the Transaction, LISI Group retained a minority stake in the Company. Precera Medical is a leading CDMO focused on the production of high-precision components and assemblies serving global medical device OEMs. The Company transforms complex designs into reliable, manufacturable solutions for the most demanding applications including surgical robotics, minimally invasive surge
ACI Worldwide Acquires European Fintech Payment Components to Augment ACI Connetic3.11.2025 13:00:00 EET | Press release
ACI Worldwide (NASDAQ:ACIW), an original innovator in global payments technology, today announced that it has acquired Payment Components, a provider of AI-powered financial messaging and Open Banking solutions. ACI will integrate Payment Components technology into ACI Connetic, accelerating the roadmap of the industry's only cloud-native unified payments platform that seamlessly integrates account-to-account (A2A) payments, card processing, and AI-powered fraud prevention within a single, modular cloud-native architecture. Founded in 2014 in Greece, Payment Components develops software for A2A payments, API management, and financial messaging, streamlining transaction orchestration without complex payment processing. Its flexible messaging layer supports a broad message set, enhancing back-office connectivity and accelerating the deployment of localized payment schemes. ACI is wholly acquiring Payment Components, including its technology, intellectual property, talent, and customer re
SLB Unveils Groundbreaking New Agentic AI Technology for the Energy Industry3.11.2025 12:00:00 EET | Press release
Global energy technology company SLB (NYSE: SLB) today announced the launch of Tela™, an agentic AI assistant purpose-built to transform the upstream energy sector. Tela leverages agentic AI to not only automate processes but transform workflows and drive better business outcomes. Tela will be embedded in SLB’s portfolio of applications and platforms, and users will interact through a simple conversational interface. This approach enables agentic AI to act as a proactive collaborator — augmenting the workforce to achieve greater productivity and efficiency at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251103326704/en/ Tela follows a common five-step agentic AI loop: observe, plan, generate, act and learn. This allows agents within Tela to proactively interact with their environment, adapt to new data, and continuously improve outcomes. Whether interpreting well logs, predicting drilling issues, or optimizing equip
Philip Morris International Publishes Updated Climate Transition Plan to Achieve Net Zero by 20403.11.2025 12:00:00 EET | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced the release of its second Climate Transition Plan (CTP 2025), presenting an updated and integrated strategy to achieve net-zero greenhouse gas (GHG) emissions across its value chain by 2040. The new plan reflects PMI’s continued commitment to a low-carbon future while aligning with science, regulatory frameworks, and stakeholder expectations, and builds on its 2021 Low-Carbon Transition Plan. Further, building on its 2022 Task Force on Climate-related Financial Disclosures (TCFD) report, the CTP 2025 details the results of a comprehensive climate change risks and opportunities (CCRO) assessment PMI conducted in 2024. “This Climate Transition Plan reinforces our commitment to sustainability as a fundamental business driver at PMI—one that is integrated, performance-based, and economically grounded," said Jacek Olczak, Chief Executive Officer. "By focusing on material climate risks and opportunities, implementing cost-effe
KCAS Bio Strengthens Board of Directors with Appointment of Paul Kirchgraber and Kurt Doyle3.11.2025 10:30:00 EET | Press release
KCAS Bio, a leading contract research organization (CRO) specializing in comprehensive bioanalytical and biomarker services, is delighted to announce the appointment of Dr. Paul Kirchgraber and Mr. Kurt Doyle to its Board of Directors. Their addition marks a significant milestone in KCAS Bio’s continued growth and strategic evolution in the global life sciences industry. KCAS Bio is headquartered in the Kansas City, Kansas metropolitan area with operating sites in the greater Philadelphia area; Lyon, France; and a partnership in Melbourne, Australia. The Company is backed by Vitruvian Partners, one of the world’s leading growth-focused investment firms. Dr. Paul Kirchgraber brings decades of leadership experience in clinical research and laboratory operations. He served as Executive Vice President and CEO of Covance, Labcorp’s Drug Development Division, where he led global teams in drug and medical device development in over 60 countries. Dr. Kirchgraber has experience running global p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom